Human papillomavirus (HPV) E7 is essential in inducing S-phase progression in differentiating epithelial cells. We have previously shown that HPV-16 E7 activity can be controlled by a direct interaction with the viral transcriptional activator E2, thereby inhibiting transforming potential of E7. We have extended these analyses to show that E2 induces a generalized re-localization of E7 within the cell nucleus, one potential consequence of which is the inhibition of E7-induced degradation of pRb. Most importantly, we show that E2 can also inhibit the ability of E7 to induce centrosome abnormalities, thus preventing aberrant mitoses. Taken together, these studies highlight the central importance of E2 in controlling the functions of E7, independently of the ability of E2 to regulate transcription.
Human papillomavirus (HPV) E7 is essential in inducing S-phase progression in differentiating epithelial cells. We have previously shown that HPV-16 E7 activity can be controlled by a direct interaction with the viral transcriptional activator E2, thereby inhibiting transforming potential of E7. We have extended these analyses to show that E2 induces a generalized re-localization of E7 within the cell nucleus, one potential consequence of which is the inhibition of E7-induced degradation of pRb. Most importantly, we show that E2 can also inhibit the ability of E7 to induce centrosome abnormalities, thus preventing aberrant mitoses. Taken together, these studies highlight the central importance of E2 in controlling the functions of E7, independently of the ability of E2 to regulate transcription. Keywords: HPV; E7; centrosomes; pRb Cellular transformation can be induced by various factors that generally contribute to the disruption of cell-cycle regulatory pathways (Vogelstein and Kinzler, 2004) . Human papillomaviruses (HPVs) are the main oncogenic factors associated with the development of cervical cancer (Doorbar, 2006) . The viral oncoproteins, E6 and E7, encoded by high-risk HPV types, most commonly HPV-16 and -18, possess activity that can contribute to the transformation of normal cervical epithelial cells into carcinomas. The E7 protein induces cellular proliferation through a number of pathways, which include the degradation of pRb (Boyer et al., 1996) , the activation of cyclin-dependent kinases (CDKs) (He et al., 2003) and the disruption of the activity of CDK inhibitors, p21 and p27 (Funk et al., 1997) , thereby activating transcription factors required for G 1 /S-phase progression. During the development of malignancy E7 can also directly abrogate normal centrosome replication, resulting in increased genetic abnormalities and genome amplification (Duensing and Mu¨nger, 2003; Patel et al., 2004) , probably in a pRbindependent manner (Duensing and Mu¨nger, 2003) . Although this activity of E7 is probably a reflection of its ability to alter CDK activity (Duensing et al., 2004) during the viral life cycle, it is also highly likely that this contributes to the generation of genomic instability during malignant progression, and can be considered as an unfortunate by-product of continued E7 expression. Thus the tight control of viral gene expression and function during infection is critical both for completion of the viral life cycle and for preventing malignant transformation.
Previously, we presented evidence that the activity of E7 can be controlled through a direct interaction with E2 (Gammoh et al., 2006) , resulting in an inhibition of transforming activity of E7. In addition, E2 also increased the stability of the E7 protein and induced its re-localization to mitotic chromosomes. These studies suggested that E2 might have multiple effects on E7, with respect to both its pattern of expression, and its ability to interact with its cellular substrates. To understand more fully the consequences of the interaction between E2 and E7 we have extended our investigation to analyse the effects of E2 on other oncogenic activities of E7.
One function of E7 that is intimately linked with the development of cancer is the induction of centrosome over-duplication, which contributes to the generation of genomic instability. Therefore we proceeded to investigate the effects of E2 on this activity of E7. Previous studies had shown that E7 induction of centrosome duplication defects could be monitored in a transient transfection assay in U2OS cells (Duensing et al., 2000) . To analyse the effects of E2 on this, centrosome numbers were monitored in U2OS cells transiently transfected with a hemagglutinin (HA)-tagged HPV-16 E7 expression plasmid, in the presence or absence of an HPV-16 E2 expression plasmid (Gammoh et al., 2006) . At 24 h after transfection, cells were treated with nocodazole for a further 24 h to induce a G 2 /M-phase arrest, in which centrosome duplication would be expected to have been completed. Cells were then fixed and stained for E2, E7 and g-tubulin, a marker of centrosomes. The results obtained are shown in Figure 1 . Cells expressing E2 alone contained up to two centrosomes per cell, which is the characteristic number for cells arrested in G 2 /M (Figure 1a, upper panel) . In contrast, a significant proportion of the cells expressing E7 contained elevated numbers of centrosomes, frequently possessing three or more per cell ( Figure 1a , middle panel), and these results are consistent with previous publications (Duensing and Mu¨nger, 2003; Duensing et al., 2004) . However, in those cells coexpressing E2 and E7, there was a marked reduction in the number of cells harbouring aberrant numbers of centrosomes ( Figure 1a , lower panel). Figure 1b shows the collated results from multiple experiments and confirms the statistically significant effects of E2 on the ability of E7 to induce abnormal centrosome duplication. The E7-induced increase in centrosome numbers is also observed in cells that have entered mitosis and, again, this is abolished by the co-expression of HPV-16 E2 ( Figure 1c ). These observations indicate that although E2 does not inhibit the normal centrosome duplication cycle of the cell, its expression nonetheless inhibits E7-induced centrosome overduplication, thus providing further evidence of the ability of E2 to regulate the oncogenic activities of E7 post-transcriptionally.
To determine whether the effects of E2 on centrosome abnormalities are specific to its ability to associate with E7, we proceeded to investigate the effects of E2 on centrosome abnormalities induced by E6. Unlike E7 however, the effects of E6 on centrosome numbers occur only when it is stably, rather than transiently, expressed (Duensing et al, 2000 (Duensing et al, , 2001a . To do this, U2OS cells were stably transfected with plasmids expressing empty pcDNA plasmid (carrying neomycin resistance), pcDNA.16E6 or pcDNA.16E7 with or without the coexpression of 16 E2, and centrosome numbers were counted as in Figure 1 . The results obtained are summarized in Figure 2a where it can be seen that the expression of E6 and E7 can each result in a comparable increase in abnormal centrosome numbers. As expected, the co-expression of 16 E2 restores centrosome numbers in E7-expressing cells. However, in E6-expressing cells, abnormal centrosome numbers are not affected by the E2 expression, suggesting that the effects of E2 on centrosome numbers are specific to E7. The expression of the viral proteins in these cell lines was also ascertained by reverse transcription (RT)-PCR using primers that specifically amplify E2 sequences (Figure 2b ), and by western blot using monoclonal Figure 1 Effects of E2 on centrosome abnormalities induced by E7. U2OS cells grown on coverslips were transiently transfected with hemagglutinin (HA)-tagged 16 E7, untagged 16 E2 or both E2 and E7 expression plasmids. At 24 h after transfection cells were treated with nocodazole for a further 24 h to arrest cells in G 2 /M phase. Cells were then fixed with paraformaldehyde (PFA) and stained using Hoechst to visualize genomic DNA, polyclonal anti-E2 (Massimi et al., 1999) and anti-HA antibodies (Y-11; Santa Cruz), to visualize E2 and E7 respectively, and for centrosomes using a monoclonal antibody against the centrosome structural protein, g-tubulin (Sigma, Milan, Italy). antibodies against HPV-16 E7 (Santa Cruz) and polyclonal antibodies against HPV-16 E2 (Massimi et al., 1999; Figure 2c ). These results are particularly interesting because numerous centrosome abnormalities are also seen in raft cultures harbouring either wild-type HPV-16 genomes or genomes mutated in E7 expression (Duensing et al., 2001) , indicating that centrosome overduplication can occur in the early stages of HPVassociated carcinogenesis and, possibly, as a result of E6 expression alone. Our results suggest that centrosome abnormalities occurring early in the HPV life cycle are most likely as a result of E6 rather than E7, whose activities are inhibited by E2.
Previous studies have suggested that the ability of E7 to induce centrosome abnormalities is independent of its ability to target pRb (Duensing and Mu¨nger, 2003) . However, pRb targeting by E7 is important for its ability to cooperate with EJ-Ras in the transformation of primary BRK cells (Heck et al., 1992) and we were therefore interested in investigating the effects of E2 on E7-induced degradation of pRb. To do this, pRb degradation assays were performed in SAOS-2 cells. These were transfected with a pRb expression plasmid, together with appropriate combinations of untagged HPV-16 E7 and HPV-16 E2 expression plasmids. After 48 h, the levels of pRb protein were ascertained by western blotting and the results obtained are shown in Figure 3a . As can be seen, E7-induced degradation of pRb was rescued in the presence of E2, even though the expression level of E7 was augmented in the presence of E2 (Figure 3b ), as reported previously (Gammoh et al., 2006 ). These results demonstrate that E2 can inhibit E7-induced degradation of pRb and provide a molecular explanation for the ability of E2 to inhibit transforming activity of E7 in BRK cells (Gammoh et al., 2006) .
The above studies demonstrate that E2 can inhibit the ability of E7 to induce aberrant centrosome duplication and target pRb for degradation. Because we had previously shown that E2 could redirect E7 to mitotic chromosomes and enhance its stability, we reasoned that E2 might be sequestering E7 in a cellular compartment where it would not normally be found when expressed alone. Because previous studies have shown that significant proportions of E2 are present within insoluble chromatin-containing complexes in the cell (Kurg et al., 2005) , we performed a series of assays to investigate the effects of E2 on the solubility of E7. To do this, U2OS cells were transfected in duplicate with either E2 or E7 separately, or in combination. One set of Figure 2 Effects of E2 on centrosome numbers stably expressed in cell lines expressing E6 or E7. Panel (a) U2OS cells were transfected with an empty pcDNA plasmid carrying neomycin resistance, untagged HPV-16 E7 (cloned into pcDNA from pJ4O.E7 using BamH1/ HindIII restriction sites) and untagged HPV-16 E6 (pcDNA) with or without the co-expression of CMV.16 E2. Cells were grown under neomycin selection for 3 weeks and centrosome numbers were analysed as in Figure 1(a) . Panel (b) To verify the expression of E2 in all the cell lines, RNA was extracted from cells using TRI reagent (Sigma) according to the manufacturer's protocol. RNA (1 mg) was subjected to reverse transcription (RT) using the RETROscript system (Ambion, Milan, Italy). No RT control was also added for assaying contamination with DNA. PCR was performed with 20 cycles and an annealing temperature of 55 1C for E2 and actin. PCR primers for actin have been described previously (Yoshinouchi et al., 2003) . 16 E2 primers were as follows: forward 5 0 -ATGGAGACTCTTTGCCAA; reverse 5 0 -TCATATAGACATAAATCCAGTAGACAC. Panel (c) To ascertain the expression of E7 in cell lines that co-express E7 and E2, U2OS cell extracts were analysed by western blotting using antibodies against g-tubulin (Sigma), 16 E2 and 16 E7.
RT-PCR
transfected cells was left untreated, whereas the other was pre-treated with a Triton-based pre-permeabilization buffer before cell extraction (Araujo et al., 2005) . In both the cases, cell extracts were separated into soluble and insoluble fractions (Grm et al., 2005) and protein levels were detected by western blot. As shown in Figure 4a , E7 alone is localized almost entirely within the soluble fraction of the cell and is completely lost when cells are pre-permeabilized. On the other hand, E2 appears in both the soluble and insoluble fractions and is resistant to the pre-permeabilization treatment. In those cells expressing both E2 and E7 there is an overall increase in the levels of E7 expression, consistent with our previous results (Gammoh et al., 2006) . However, the bulk of this increase is in the insoluble fraction and, most importantly, the E7 protein in this fraction also becomes resistant to the pre-permeabilization treatment. In contrast, the E7 protein that remains in the soluble fraction is still largely removed by the pre-permeabilization treatment.
This analysis was then repeated and the pattern of E7 and E2 expression was monitored by immunofluorescence. The results obtained are shown in Figure 4b . Although E2 and E7 are expressed in the nucleus, prepermeabilization completely abolishes E7 expression, whereas E2 can still be detected in the nucleus. In contrast, when E2 and E7 are co-expressed, there is a strong retention of E7 following the pre-permeabilization treatment.
Based on these studies one would predict that E7 would become more soluble in HPV-immortalized keratinocytes once the viral genome has become integrated and E2 expression is lost. To investigate this directly we used a series of HPV-16-immortalized keratinocyte paired cell lines that contain either episomal or integrated HPV-16 DNA. The parental episomal cells were subjected to extensive passage in the absence of feeders until viral genome integration occurred, which was verified by Southern blot analysis and, as can be seen from Figure 4d , the bulk of the HPV-16 genome was integrated by passage 20. The episomal/integrated cell line was then extracted and divided into soluble and insoluble fractions. The pattern of E7 expression was then monitored by western blot analysis and the results obtained are shown in Figure 4c . As can be seen, E7 expression is high in both the integrated cell line and in the CaSKi cells that were used as a positive control. However, the E7 in these cells is found predominantly in the soluble fractions. In contrast, E7 expression is low in the episomal cell lines (three times the amount of cell extract was required to detect E7 compared with that required in the integrated cells), however a significant proportion of this is detectable in the insoluble fraction, consistent with the notion that a proportion of E7 is rendered insoluble by the presence of E2. Taken together, these results indicate that E2 can redirect E7 to an insoluble compartment within the nucleus.
We had previously shown that E2 had profound effects on both the biological and biochemical activities of the HPV E7 oncoprotein (Gammoh et al., 2006) . In this study we have extended these studies to define the underlying mechanisms behind E2 modulation of E7 function. We show that E2 induces a marked relocalization of the E7 protein from the soluble fraction to the insoluble fraction of the cell. Because previous studies had shown that E2 is largely associated with chromatin (Kurg et al., 2005; Donaldson et al., 2007) , it is tempting to suggest that E2 is also recruiting E7 onto chromatin-containing complexes. At present it is not clear what this recruitment might mean for E7 function, although it is conceivable that this may result not only in the regulation of some E7 functions as reported here, but also in the gain of other, as yet unknown, activities of the protein. It is also worth noting that the relative levels of E2 and E7 may vary with respect to each other during keratinocyte differentiation, which in turn would also be expected to alter the degree to which E2 can modulate E7 function. However it is clear that E2 will inevitably alter the amount of E7 that is available to interact with the cellular proteins that are found within the nuclear soluble fraction. This notion is supported by the results obtained from pRb degradation assays and the induction of centrosome abnormalities, where E2 is a potent inhibitor both of E7-induced degradation of pRb, and of E7-induced centrosome over-duplication. In the case of pRb, this would seem to be the most likely explanation for the inhibitory effects of E2 on E7 transformation of primary BRK cells. It is also tempting to suggest that loss of E2 during HPV-induced malignancy may directly alter E7 function such that there is enhanced degradation of its target proteins with 
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Low Exposure High Exposure * * * * * * Figure 4 E7 is re-localized to the insoluble fraction of the cell in the presence of E2. (a) U2OS cells were transfected in duplicate with plasmids expressing either E2 or E7 alone or in combination. One set of transfected cells was left untreated, whereas the other was treated with a pre-permeabilization buffer for 7 min (Araujo et al., 2005) . In both cases, cell extracts were separated into soluble and insoluble fractions (Grm et al., 2005) and protein levels were detected by western blot using specific antibodies against E2 (as above) or E7 (ED17; Santa Cruz). (b) U2OS cells grown on coverslips were transfected in a parallel experiment. After treatment with the pre-permeabilization buffer, cells were fixed with paraformaldehyde (PFA) and analysed by immunofluorescence using rabbit anti-E2 (green) and mouse anti-E7 (red) antibodies. (c) Western blot analysis of HPV-16 E7 expression in HPV-16-immortalized keratinocytes. Cells were grown extensively until episomes were lost and the pattern of E7 expression in the soluble and insoluble cell fractions was determined by western blot analysis using anti-E7 monoclonal antibody (kindly provided by Karl Mu¨nger). In the integrated line and in CaSKi cells E7 is detectable predominantly within the soluble fraction, whereas in the episomal line E7 is readily detectable in the insoluble fraction. It should be noted that the western blot was performed on the same membrane but, due to low levels of E7 expression in the episomal line that section of the blot had to be exposed for longer. (d) Southern blot analysis (low and high exposure) HPV-16 DNA in keratinocytes grown in the absence of feeders. Total genomic DNA was digested with HindIII (should not digest the HPV genome) and BamHI (linearizes the HPV DNA) and probed for HPV-16 DNA. Note that at p0 the genome is exclusively episomal and by p20 the genome is predominantly integrated into the host genome. A full colour version of this figure is available at the Oncogene journal online.
concomitant induction of centrosome abnormalities, thereby directly contributing to the progression of the malignancy.
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